Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490154 | 1.00 | MRGPRX4 (0.54) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL21044004 | 0.98 | MRGPRX4 (0.53) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL183978 | 0.84 | MRGPRX4 (0.52) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30022926 | 0.84 | MRGPRX4 (0.52) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6117260 | 0.84 | CYP1A2 (0.53) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7671391 | 0.84 | MRGPRX4 (0.52) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1698714 | 0.83 | CYP1A2 (0.72) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21199935 | 0.83 | MRGPRX4 (0.51) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22451835 | 0.83 | MRGPRX4 (0.51) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22002661 | 0.83 | MRGPRX4 (0.58) | MRGPRX4CYP1A2SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250325718-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | JANSSEN BIOTECH INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-12378200-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ORSOBIO, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| EP-2129670-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2001872-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| US-5559134-A | Leukotriene-B4 antagonists, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378200-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ALDH7A1, ACMSD, AMD1 | MRGPRX4 2962/4885CYP1A2 1217/4885SMN1; SMN2 2338/4885 |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | MRGPRX4 172/4885CYP1A2 1326/4885SMN1; SMN2 3544/4885 |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | MRGPRX4 286/4885CYP1A2 208/4885SMN1; SMN2 2462/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | MRGPRX4 302/4885CYP1A2 3054/4885SMN1; SMN2 2018/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MRGPRX4 331/4885CYP1A2 1423/4885SMN1; SMN2 2170/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885CYP1A2 1885/4885SMN1; SMN2 4376/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MRGPRX4 178/4885CYP1A2 1392/4885SMN1; SMN2 3746/4885 |
| US-20250325718-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | KLK3, KLK2, KLKB1 | MRGPRX4 1398/4885CYP1A2 4090/4885SMN1; SMN2 4198/4885 |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | CLASP1, CLTC, CD47 | MRGPRX4 881/4885CYP1A2 4570/4885SMN1; SMN2 3975/4885 |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | MRGPRX4 445/4885CYP1A2 4705/4885SMN1; SMN2 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.